Drug Profile
RTL 1000
Alternative Names: RTL1000; VG1000Latest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator Oregon Health & Science University
- Developer Artielle ImmunoTherapeutics
- Class
- Mechanism of Action T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 May 2018 No recent reports of development identified for phase-I development in Multiple-sclerosis in USA (IV, Infusion)
- 18 May 2016 Phase I development is ongoing in USA
- 19 Apr 2010 Final adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in relapsing-remitting multiple sclerosis presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN-2010)